HZHedong Zhang

Hedong Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hedong Zhang has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • Gongbin Lan

    Department of Kidney Transplantation, The Second Xiangya Hospital of Central South University, Changsha, China

    4 shared publications
  • Helong Dai

    Department of Kidney Transplantation, Center of Organ Transplantation, The Second Xiangya Hospital, Central South University, Changsha, China

    4 shared publications
  • Fenghua Peng

    Department of Kidney Transplantation, Center of Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China; Clinical Research Center for Organ Transplantation in Hunan Province, Central South University, Changsha, China

    2 shared publications
  • Jiajie Qin

    Department of Kidney Transplantation, Center of Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China, csu.edu.cn

    2 shared publications
  • Liang Tan

    Department of Kidney Transplantation, Center of Organ Transplantation, The Second Xiangya Hospital, Central South University, Changsha 410011, China

    2 shared publications
  • Longkai Peng

    Department of Kidney Transplantation, Center of Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China; Clinical Research Center for Organ Transplantation in Hunan Province, Central South University, Changsha, China

    2 shared publications

Latest Publications

  • Open Access

    IL‐27: A Double‐Edged Sword in Immune Regulation via JAK‐STAT Orchestration

    by Xiangqi Zhang, Chen Feng, Ye Xu, Yingqi Zeng, Qiulin Luo, Jiajie Qin, Tengfang Li, Longkai Peng, Hedong Zhang, Helong Dai

    Interleukin‐27 (IL‐27) is a multifunctional cytokine produced mainly by innate immune cells that regulates immune responses primarily through the Janus kinase (JAK)‐signal transducer and activator of transcription (STAT) signaling pathway. The role of IL‐27 in immune regulation is complex and often paradoxical, with both pro‐inflammatory and immunosuppressive functions described, depending on the specific immune context and cellular milieu. Here, we systematically discuss the dual regulatory roles of IL‐27 in immune regulation, with a particular emphasis on its role in the JAK‐STAT signaling pathway. We highlight the latest advancements in understanding the functional differences and molecular mechanisms of IL‐27 in both adaptive and innate immune cells. We further elaborate on IL‐27‐mediated immune regulation through nonimmune cells. Understanding the multifaceted and context‐dependent properties of IL‐27 is essential for deciphering the precise role of IL‐27 in health and disease and for developing targeted immunotherapies. This review systematically analyzes the “double‐edged sword” mechanism of IL‐27, providing a theoretical and translational basis for targeting the JAK‐STAT pathway.

  • Open Access

    Association between drinking water type and kidney stone risk in U.S. adults: a cross-sectional analysis of NHANES 2009–2016 data

    by Jiajie Qin, Jiyuan Li, Hedong Zhang, Hao Wen, Ye Xu, Qiulin Luo, Jiawei Peng, Tengfang Li, Xiangqi Zhang, Rongzheng Nie, et al.

    Purpose: While fluid intake and trace elements are known to influence kidney stone risk, the impact of drinking water type remains unclear. This study aimed to systematically evaluate the association between water source and kidney stone prevalence. Methods: This analysis included 10 246 adults (≥20 years) from the National Health and Nutrition Examination Survey database (2009–2016). Kidney stone history was self-reported, and drinking water sources were assessed through 24-hour dietary recalls. We employed multivariable-adjusted logistic regression models, adjusting for potential confounders including age, sex, race, body mass index (BMI), physical activity, calcium intake, smoking status, alcohol consumption, diabetes, and hypertension, to evaluate the association between drinking water type and kidney stone occurrence. To assess potential nonlinear relationships, restricted cubic spline (RCS) models were utilized. Additionally, cluster analysis was performed to categorize participants into distinct subgroups based on water consumption patterns. Finally, propensity score matching (PSM) and subgroup analyses were conducted to further validate the robustness of the findings. Results: Logistic regression suggested that higher tap water intake was significantly inversely related with kidney stone prevalence [adjusted odds ratio (OR) = 0.678, 95% confidence interval (CI): 0.491–0.938, P for trend = 0.0177], suggesting a 32% lower odds of kidney stones with increased tap water consumption. However, bottled water intake was not significantly associated with kidney stone risk. The RCS model revealed a linear decreasing trend between tap water intake and kidney stone risk ( P for all P for nonlinear = 0.8505). Cluster analysis showed that high tap water intake and low bottled water intake were associated with a lower prevalence of kidney stones. This association persisted in the propensity score-matched models and subgroup analyses after adjustment for bottled water intake. Conclusion: Our study revealed an inverse association between tap water intake and kidney stone prevalence among U.S. adults. Bottled water intake had no statistically significant effect on stone formation. These results suggest that higher tap water intake may confer a protective effect against kidney stone formation. These findings could guide public health recommendations on hydration habits.


  • Trametinib alleviates lipopolysaccharide-induced acute kidney injury by inhibiting macrophage polarization through the PI3K/Akt pathway

    by Yingqi Zeng, Wenjia Yuan, Chen Feng, Longkai Peng, Xubiao Xie, Fenghua Peng, Tengfang Li, Minjie Lin, Hedong Zhang, Helong Dai


  • Open Access

    Excellent clinical outcomes of renal transplant from pediatric deceased donors with acute kidney injury

    by Qiuhao Liu, Hedong Zhang, Mingda Zhong, Liang Tan, Shanbiao Hu, Longkai Peng, Xubiao Xie, Gongbin Lan

    The use of kidneys from deceased donors with acute kidney injury (AKI) to expand the donor pool is an ongoing trend. Prior research on the utilization of AKI donor kidneys, especially from pediatric AKI donors, was limited and has been subject to small sample sizes. In this study, we aimed to evaluate the safety and effectiveness of early post-transplantation outcomes in pediatric deceased donors with AKI. This retrospective study compared the clinical results (including delayed graft function [DGF], acute rejection, patient and death-censored graft survival rates and renal function post-transplant) of kidney transplantation from deceased donors who were categorized as pediatric donors and adult donors with or without AKI, as defined by the Kidney Disease: Improving Global Outcomes (KIDGO) criteria, at our center between January 2018 and December 2020. Of the 740 patients, 154 received kidneys from pediatric donors (with AKI group [n = 41]; without AKI group [n = 113]), and 586 received kidneys from adult donors (with AKI group [n = 218]; without AKI group [n = 368]). The baseline characteristics were similar in both cohorts. No significant difference was observed in 1-year patient survival, death-censored graft survival, or acute rejection between the AKI and non-AKI groups in both the pediatric and adult cohorts. However, compared with those transplanted with adult AKI kidneys, those transplanted with pediatric AKI kidneys showed a superior recovery of allograft function. In pediatric cohorts, no significant difference was found in serum creatinine/estimated glomerular filtration rate (SCr/eGFR) between the AKI and non-AKI groups, even in the first week post-transplant. In contrast, the post-transplant SCr/eGFR level of the AKI group recipients in adult cohorts did not recover to a level statistically similar to that of non-AKI recipients, even at 6-months post-transplant. Nonetheless, AKI kidney recipients were at an increased risk of DGF in both pediatric (34.1% vs. 16.8%) and adult (38.5% vs. 17.4%) cohorts. Kidney transplantation from deceased donors with AKI has short-term clinical outcomes comparable to those of non-AKI kidney transplantation. Pediatric AKI kidneys have a superior recovery of allograft function. The transplant community should utilize this donor pool to minimize waiting-list-related mortalities.


  • Open Access

    Excellent Clinical Outcomes of Renal Transplant from Pediatric Deceased Donors with Acute Kidney Injury

    by Qiuhao Liu, Hedong Zhang, Mingda Zhong, Liang Tan, Shanbiao Hu, Longkai Peng, Xubiao Xie, Gongbin Lan

    Background: The use of kidneys from deceased donors with acute kidney injury (AKI) to expand the donor pool is an ongoing trend. Prior research on the utilization of AKI donor kidneys, especially from pediatric AKI donors, was limited and has been subject to small sample sizes. In this study, we aimed to evaluate the safety and effectiveness of early post-transplantation outcomes in pediatric deceased donors with AKI. Methods: This retrospective study compared the clinical results (including delayed graft function [DGF], acute rejection, patient and death-censored graft survival rates and renal function post-transplant) of kidney transplantation from deceased donors who were categorized as pediatric donors and adult donors with or without AKI, as defined by the Kidney Disease: Improving Global Outcomes (KIDGO) criteria, at our center between January 2018 and December 2020. Results: Of the 740 patients, 154 received kidneys from pediatric donors (with AKI group [n=41]; without AKI group [n=113]), and 586 received kidneys from adult donors (with AKI group [n=218]; without AKI group [n=368]). The baseline characteristics were similar in both cohorts. No significant difference was observed in 1-year patient survival, death-censored graft survival, or acute rejection between the AKI and non-AKI groups in both the pediatric and adult cohorts. However, compared with those transplanted with adult AKI kidneys, those transplanted with pediatric AKI kidneys showed a superior recovery of allograft function. In pediatric cohorts, no significant difference was found in serum creatinine/estimated glomerular filtration rate (SCr/eGFR) between the AKI and non-AKI groups, even in the first week post-transplant. In contrast, the post-transplant SCr/eGFR level of the AKI group recipients in adult cohorts did not recover to a level statistically similar to that of non-AKI recipients, even at 6-months post-transplant. Nonetheless, AKI kidney recipients were at an increased risk of DGF in both pediatric (34.1% vs. 16.8%) and adult (38.5% vs. 17.4%) cohorts. Conclusions: Kidney transplantation from deceased donors with AKI has short-term clinical outcomes comparable to those of non-AKI kidney transplantation. Pediatric AKI kidneys have a superior recovery of allograft function. The transplant community should utilize this donor pool to minimize waiting-list-related mortalities.


  • Open Access

    Utilization of HCV Viremic Kidneys with Genotyping/Subtyping‐Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China

    by Hedong Zhang, Qiuhao Liu, Shanbiao Hu, Mingda Zhong, Fenghua Peng, Yong Guo, Chunhua Fang, Manhua Nie, Liang Tan, Helong Dai, et al.

    Background. Owing to the advent of pangenotypic direct‐acting antiviral agents (DAAs) for hepatitis C virus (HCV) treatment, utilization of HCV‐infected deceased donor kidneys with simplified genotyping/subtyping‐free sofosbuvir/velpatasvir (SOF/VEL) treatment strategy is now becoming a promising strategy for expanding the organ donor pool. Methods. This retrospective, comparative, single‐center study included HCV viremic donor kidneys that were transplanted to 9 HCV‐positive (HCV Ab‐positive) recipients (D+/R+ group) and 14 HCV‐negative recipients (D+/R‐ group) from May 2018 to January 2021. Both groups received prophylaxis with SOF/VEL treatment within 1‐week posttransplant devoid of HCV genotyping/subtyping. The primary outcomes were sustained virologic response 12 weeks after completion of therapy (SVR12) and graft survival at 1‐year posttransplant. Results. Baseline characteristics were similar between the HCV D+/R‐ and D+/R+ groups. The mean age of all recipients was 39.09 ± 9.65 (SD) years, and 73.9% were male. A total of 92.9% (13 out of 14) recipients had pretreatment HCV viremia in the D+/R‐ group. The pretreatment HCV viral load in the D+/R+ group (5.98, log 10 IU/mL; IQR, 5.28‐6.53) was significantly higher than that in the D+/R‐ group (3.61, log 10 IU/mL; IQR, 2.57‐4.57). After SOF/VEL treatment, SVR12 was achieved in all recipients, with a 100% 1‐year patient and graft survival rates. The D+/R+ group had a higher incidence of abnormal liver function (44.4% vs. 7.1%). No significant difference was observed between the two groups in terms of DGF, acute rejection, ALT, serum creatinine, and eGFR within 1‐year posttransplant. No severe adverse events associated with either HCV viremia or SOF/VEL were observed. Conclusions. Using a simplified genotyping/subtyping‐free SOF/VEL treatment strategy, kidneys from hepatitis C viremic donors for both infected and uninfected recipients presented with safe, excellent, and comparable 1‐year outcomes, which can safely expand the donor pool. HCV‐positive donor kidneys should be utilized regularly, regardless of the recipient’s HCV status.


  • Open Access

    The Role of Regulatory B cells in Kidney Diseases

    by Wang Long, Hedong Zhang, Wenjia Yuan, Gongbin Lan, Zhi Lin, Longkai Peng, Helong Dai

    B cells, commonly regarded as proinflammatory antibody-producing cells, are detrimental to individuals with autoimmune diseases. However, in recent years, several studies have shown that regulatory B (Breg) cells, an immunosuppressive subset of B cells, may exert protective effects against autoimmune diseases by secretion of inhibitory cytokines such as IL-10. In practice, Breg cells are identified by their production of immune-regulatory cytokines, such as IL-10, TGF-β, and IL-35, however, no specific marker or Breg cell-specific transcription factor has been identified. Multiple phenotypes of Breg cells have been found, whose functions vary according to their phenotype. This review summarizes the discovery, phenotypes, development, and function of Breg cells and highlights their potential therapeutic value in kidney diseases.